Adicet Bio, Inc. - Common Stock, par value $0.0001 (ACET)
CUSIP: 007002108
Q4 2025 13F Holders as of 31 Dec 2025
- Type / Class
- Equity / Common Stock, par value $0.0001
- Shares outstanding
- 9,599,852
- Total 13F shares
- 60,511
- Share change
- -51,340,484
- Total reported value
- $509,503
- Price per share
- $8.42
- Number of holders
- 1
- Value change
- -$48,502,668
- Number of sells
- 53
Quarterly Holders Quick Answers
What is CUSIP 007002108?
CUSIP 007002108 identifies ACET - Adicet Bio, Inc. - Common Stock, par value $0.0001 in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 007002108:
Top shareholders of ACET - Adicet Bio, Inc. - Common Stock, par value $0.0001 (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC |
13F
|
Company |
119%
|
11,447,140
|
$9,274,473 | — | 30 Sep 2025 | |
| TANG CAPITAL MANAGEMENT LLC |
13F
13D/G
|
Company |
0.1%
from 13D/G
|
8,223,612
|
$6,662,770 | — | 30 Sep 2025 | |
| RA CAPITAL MANAGEMENT, L.P. |
13F
|
Company |
79%
|
7,541,000
|
$6,109,718 | — | 30 Sep 2025 | |
| FRANKLIN RESOURCES INC |
13D/G
|
— |
6.5%
|
626,571
|
$5,238,572 | $0 | 31 Dec 2025 | |
| Woodline Partners LP |
13D/G
|
— |
6.5%
|
625,000
|
$5,181,250 | $0 | 31 Dec 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
39%
|
3,751,617
|
$3,039,560 | — | 30 Sep 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
34%
|
3,272,522
|
$2,650,743 | — | 30 Sep 2025 | |
| Carlyle Group Inc. |
13F
|
Company |
31%
|
2,948,718
|
$2,388,756 | — | 30 Sep 2025 | |
| ACADIAN ASSET MANAGEMENT LLC |
13F
|
Company |
24%
|
2,265,491
|
$1,835,000 | — | 30 Sep 2025 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
19%
|
1,828,949
|
$1,481,814 | — | 30 Sep 2025 | |
| Carl L. Gordon |
3/4/5
|
Director, 10%+ Owner |
—
mixed-class rows
|
684,857
mixed-class rows
|
$941,594 | — | 21 Aug 2024 | |
| REGENERON PHARMACEUTICALS, INC. |
13F
|
Company |
10%
|
968,183
|
$784,422 | — | 30 Sep 2025 | |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC |
13F
|
Company |
9.4%
|
901,600
|
$730,476 | — | 30 Sep 2025 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
8.9%
|
854,568
|
$692,371 | — | 30 Sep 2025 | |
| TWO SIGMA ADVISERS, LP |
13F
|
Company |
8.1%
|
780,982
|
$632,752 | — | 30 Sep 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
7.4%
|
706,334
|
$572,440 | — | 30 Sep 2025 | |
| Alyeska Investment Group, L.P. |
13F
|
Company |
6.8%
|
655,665
|
$531,220 | — | 30 Sep 2025 | |
| RBF Capital, LLC |
13F
|
Company |
6.4%
|
617,319
|
$500,152 | — | 30 Sep 2025 | |
| BlackRock, Inc. |
13F
|
Company |
6.1%
|
585,377
|
$474,272 | — | 30 Sep 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
6.1%
|
583,948
|
$473,115 | — | 30 Sep 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
5.9%
|
565,953
|
$458,535 | — | 30 Sep 2025 | |
| Schonfeld Strategic Advisors LLC |
13F
|
Company |
5%
|
479,108
|
$388,171 | — | 30 Sep 2025 | |
| JOHNSON & JOHNSON |
13F
|
Company |
3.8%
|
364,472
|
$295,295 | — | 30 Sep 2025 | |
| Francesco Galimi |
3/4/5
|
SVP & Chief Medical Officer |
—
mixed-class rows
|
476,878
mixed-class rows
|
$244,322 | — | 05 Jun 2024 | |
| WEALTHEDGE INVESTMENT ADVISORS, LLC |
13F
|
Company |
3.1%
|
300,054
|
$243,104 | — | 30 Sep 2025 | |
| BARCLAYS PLC |
13F
|
Company |
3.1%
|
300,000
|
$243,060 | — | 30 Sep 2025 | |
| Aya Jakobovits |
3/4/5
|
Director |
—
mixed-class rows
|
176,276
mixed-class rows
|
$214,323 | — | 21 Aug 2024 | |
| STATE STREET CORP |
13F
|
Company |
2.5%
|
244,186
|
$197,840 | — | 30 Sep 2025 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
1.9%
|
186,200
|
$150,859 | — | 30 Sep 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
1.5%
|
140,373
|
$113,730 | — | 30 Sep 2025 | |
| Lloyd Klickstein |
3/4/5
|
Director |
—
mixed-class rows
|
134,966
mixed-class rows
|
$66,225 | — | 11 Jun 2025 | |
| Vontobel Holding Ltd. |
13F
|
Company |
0.83%
|
80,000
|
$65,176 | — | 30 Sep 2025 | |
| ROYAL BANK OF CANADA |
13F
|
Company |
0.83%
|
80,000
|
$65,000 | — | 30 Sep 2025 | |
| Virtu Financial LLC |
13F
|
Company |
0.83%
|
79,916
|
$65,000 | — | 30 Sep 2025 | |
| Rangeley Capital, LLC |
13F
|
Company |
0.78%
|
75,000
|
$60,765 | — | 30 Sep 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.77%
|
73,682
|
$59,697 | — | 30 Sep 2025 | |
| BLUEFIN CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.7%
|
66,854
|
$54,165 | — | 30 Sep 2025 | |
| XTX Topco Ltd |
13F
|
Company |
0.61%
|
58,139
|
$47,104 | — | 30 Sep 2025 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
0.55%
|
52,963
|
$42,911 | — | 30 Sep 2025 | |
| MARSHALL WACE, LLP |
13F
|
Company |
0.54%
|
51,733
|
$41,904 | — | 30 Sep 2025 | |
| Squarepoint Ops LLC |
13F
|
Company |
0.48%
|
46,427
|
$37,615 | — | 30 Sep 2025 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.42%
|
40,370
|
$32,708 | — | 30 Sep 2025 | |
| Abacus Planning Group, Inc. |
13F
|
Company |
0.38%
|
36,764
|
$29,786 | — | 30 Sep 2025 | |
| TWO SIGMA SECURITIES, LLC |
13F
|
Company |
0.26%
|
25,274
|
$20,477 | — | 30 Sep 2025 | |
| UBS Group AG |
13F
|
Company |
0.22%
|
21,438
|
$17,365 | — | 30 Sep 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.21%
|
20,607
|
$16,692 | — | 30 Sep 2025 | |
| Qube Research & Technologies Ltd |
13F
|
Company |
0.21%
|
20,257
|
$16,412 | — | 30 Sep 2025 | |
| HRT FINANCIAL LP |
13F
|
Company |
0.19%
|
18,627
|
$15,000 | — | 30 Sep 2025 | |
| Steve Dubin |
3/4/5
|
Director |
—
mixed-class rows
|
49,100
mixed-class rows
|
$13,847 | — | 11 Jun 2025 | |
| Mariner, LLC |
13F
|
Company |
0.15%
|
14,850
|
$12,031 | — | 30 Sep 2025 |
Institutional Holders of Adicet Bio, Inc. - Common Stock, par value $0.0001 (ACET) as of Q4 2025
As of 31 Dec 2025,
Adicet Bio, Inc. - Common Stock, par value $0.0001 (ACET) was held by
1 institutional
shareholder
that filed Form 13F with the SEC.
Together, they reported ownership of
60,511 shares.
The largest 1 holders included
REGENERON PHARMACEUTICALS, INC..
This page lists
1
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q4 2025 vs Q3 2025 Across Filers
Q3 2025 holders
53
Q4 2025 holders
1
Holder diff
-52
| Investor | Q3 2025 Shares | Q4 2025 Shares | Share Diff | Share Chg % | Q3 2025 Value $ | Q4 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.